Effect of Oral Cinnamon Intervention in Metabolic Syndrome

Effect of Intervention With Oral Cinnamon on Metabolic Profile and Body Composition of Asian Indians With Metabolic Syndrome in North India: A 16 Week Double Blind Placebo Control Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02455778

Enrollment

103

Registered

2015-05-28

Start date

2011-08-31

Completion date

2013-04-30

Last updated

2015-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Brief summary

This double blind placebo control study with supplementation of oral Cinnamon is being conducted to test the hypothesis that in subjects with Metabolic Syndrome oral cinnamon may lead to improvement in body composition and metabolic parameters.

Interventions

DIETARY_SUPPLEMENTCinnamon

DIETARY_SUPPLEMENTPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

25 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

1. Subjects aged between 25 -65 years 2. Subjects identified with any three of following: 1. Fasting blood glucose ≥100 mg/ dL 2. Waist circumference ≥ 90 cm ( males) ≥ 80 cm (females) 3. Triglycerides ≥ 150 mg/dL 4. High density lipoprotein cholesterol ≤ 40 mg/dL ( in males) , ≤ 50 mg/dL (in females) 5. Blood pressure Systolic BP ≥ 130 mm Hg 6. Diastolic BP ≥ 85 mm Hg 3. Subjects who were willing to participate in the study. 4. Subjects, if on medication for high blood pressure were stable and there was no change in the dosage for the past 3 months.

Exclusion criteria

1. Subjects suffering from other chronic diseases and metabolic complications such as cardiovascular disease, diabetes, renal disease, myocardial infarction and other endocrine disorders. 2. Subjects who were allergic to wheat flour and cinnamon. 3. Subjects who were on medication of anti dyslipidemic or hypoglycemic drugs. 4. Subjects who had undergone bypass procedure. 5. Subjects suffering from any debilitating disease such as tuberculosis, HIV etc. 6. Subjects suffering from uncontrolled hypothyroidism/ hyperthyroidism 7. Pregnant and lactating mothers

Design outcomes

Primary

Measure	Time frame
Fasting Blood Glucose	baseline to 4 months

Secondary

Measure	Time frame
HbA1c	baseline to 4 months
Lipid profile	baseline to 4 months
Body fat percentage	baseline to 4 months
Blood pressure	baseline to 4 months

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026